<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Zealand-Pharma-DK0060257814">Zealand Pharma</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/08/3308282/0/en/Zealand-Pharma-Transactions-related-to-share-buy-back-program-week-23-2026.html">Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)</a>
    </div>

      <div class="me-0 me-md-5">
        Company announcement No. 23 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 23, 2026) Copenhagen, Denmark, June 8, 2026 – Zealand Pharma A/S (&quot;the Company&quot; or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Zealand-Pharma-DK0060257814">Zealand Pharma</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/08/3308278/0/en/Zealand-Pharma-increases-its-share-capital-as-a-result-of-the-exercise-of-employee-warrants.html">Zealand Pharma increases its share capital as a result of the exercise of employee warrants</a>
    </div>

      <div class="me-0 me-md-5">
        Company announcement – No. 22 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 8, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Zealand-Pharma-DK0060257814">Zealand Pharma</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/pharma/zealand-pharma-shares-slide-after-boehringer-study-shows-obesity-shots-side-effects-a624e7b4">Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot&#39;s Side Effects</a>
    </div>

      <div class="me-0 me-md-5">
        Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Zealand-Pharma-DK0060257814">Zealand Pharma</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">CNBC</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.cnbc.com/2026/06/08/weight-loss-drug-stock-zealand-pharma-data-ada.html">Weight loss drug maker sinks 25% after new safety data spooks investors</a>
    </div>

      <div class="me-0 me-md-5">
        Shares of Zealand Pharma plummeted as much as 26% after new data on its experimental weight-loss medicine raised concerns over its side effects. &quot;Safety/tolerability remains the key issue,&quot; said Barcalys analysts.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Zealand-Pharma-DK0060257814">Zealand Pharma</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Market Watch</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.marketwatch.com/story/zealand-pharma-loses-a-fifth-of-its-value-as-many-users-gave-up-taking-weight-loss-drug-during-trial-80293179">Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial</a>
    </div>

      <div class="me-0 me-md-5">
        Zealand Pharma lost a fifth of its market value on Monday after a late-stage trial found many patients stopped taking a weight-loss drug due to tolerability problems.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Zealand-Pharma-DK0060257814">Zealand Pharma</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/zealand-pharma-shares-drop-20-obesity-drug-side-effects-raise-concerns-2026-06-08/">Zealand Pharma shares drop 20% as obesity drug side effects raise concerns</a>
    </div>

      <div class="me-0 me-md-5">
        Zealand ​Pharma&#39;s shares ‌fell more than ​20% ​in early trade ⁠on ​Monday after ​trial data showed its ​obesity ​drug survodutide had ‌worse ⁠side effects and higher ​patient ​dropout ⁠rates than ​rival ​treatments.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Zealand-Pharma-DK0060257814">Zealand Pharma</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/07/3307740/0/en/Zealand-Pharma-announces-Boehringer-Ingelheim-s-survodutide-Phase-III-trial-in-people-living-with-obesity-showed-targeted-34-visceral-and-63-liver-fat-reduction-while-minimizing-le.html">Zealand Pharma announces Boehringer Ingelheim&#39;s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis</a>
    </div>

      <div class="me-0 me-md-5">
        Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim&#39;s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which m...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Zealand-Pharma-DK0060257814">Zealand Pharma</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/zealand-touts-promising-tolerability-data-obesity-drug-mid-stage-study-2026-06-05/">Zealand touts promising tolerability data for obesity drug in mid-stage study</a>
    </div>

      <div class="me-0 me-md-5">
        Zealand Pharma said on Friday its experimental obesity drug, co-developed with Swiss partner Roche , showed encouraging tolerability in a mid-stage trial, bolstering ​its push to take on market leaders with a potentially ‌gentler alternative to existing blockbuster treatments.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Zealand-Pharma-DK0060257814/load_more?page=6">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>